CN1994403A - Pharmaceutical composition for promoting blood circulation and preparation method thereof - Google Patents
Pharmaceutical composition for promoting blood circulation and preparation method thereof Download PDFInfo
- Publication number
- CN1994403A CN1994403A CN 200610163849 CN200610163849A CN1994403A CN 1994403 A CN1994403 A CN 1994403A CN 200610163849 CN200610163849 CN 200610163849 CN 200610163849 A CN200610163849 A CN 200610163849A CN 1994403 A CN1994403 A CN 1994403A
- Authority
- CN
- China
- Prior art keywords
- radix
- blood circulation
- pharmaceutical composition
- parts
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000017531 blood circulation Effects 0.000 title claims description 33
- 230000001737 promoting effect Effects 0.000 title claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 15
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 15
- 239000006187 pill Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 13
- 241000222336 Ganoderma Species 0.000 claims description 10
- 241000237903 Hirudo Species 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 6
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 5
- 208000034189 Sclerosis Diseases 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 240000008397 Ganoderma lucidum Species 0.000 abstract 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract 1
- 241000545744 Hirudinea Species 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229930188824 alisol Natural products 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 37
- 239000003814 drug Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- -1 flavone compound Chemical class 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000009427 jiangzhi Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000008802 xuezhikang Substances 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000010068 shuxuening Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000009561 tongxinluo Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical pill composition for treating hyperlipemia, cardiovascular and cerebrovascular sclerosis and coronary disease, as well as the process for preparation, wherein the composition comprises the following constituents: astragalus root 6-8 parts, fleece-flower root 4-6 parts, red sage root 6-8 parts, ganoderma lucidum 3-5 parts, notoginseng 2-4 parts, rhizome of Sichuan lovage 2-4 parts, red peony root 3-5 parts, alisol 3-5 parts, haw 6-8 part, leech 2-4 parts and lotus leaves 2-40 parts.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for promoting blood circulation and preparation method thereof, especially treat the pharmaceutical composition for promoting blood circulation of hyperlipemia, cerebrovascular sclerosis, coronary heart disease.
Background technology
Along with economic development, living standards of the people improve, the change of diet structure, fast pace, high efficiency working environment, several big reason that causes cardiovascular and cerebrovascular disease in recent years---hypertension, blood are sticking, blood is thick, fat, diabetes, coronary heart disease etc., obvious ascendant trend occurs in China.
According to epidemiology, sick bed and experimentation confirm that hyperlipidemia is atherosclerotic primary risk factor, with the sickness rate of coronary heart disease, cardiovascular and cerebrovascular disease direct relation are arranged; To human health, civilization forms serious restraining factors to cardiovascular and cerebrovascular disease with its high cause of the death, high disability rate, high mortality and expensive treatment cost.At present in the medicine on the market, Chinese patent medicine is suited the medicine to the illness not clear, drug effect is single, as SHUXUENING pin, fragrant red pin, thromboembolism cleansing pin, TONGXINLUO JIAONANG, Herba Erigerontis tablet, XUESAITONG JIAONANG, Radix Salviae Miltiorrhizae drop pill etc. have the effect of activating blood circulation to dissipate blood stasis, blood pressure lowering coronary dilating, and other effect is very faint: diabetes pill is that the hypoglycemic pcm of representative has blood sugar lowering, improve the symptom of thirsty, polydipsia, polyphagia, and other effect is faint; Current can blood fat reducing, and appropriate of XUEZHIKANG JIAONANG, the blood fat of curative effect certainly have the effect that spleen invigorating removes humidifying fat, and function of promoting blood circulation to disperse blood clots is arranged slightly.In the middle of the Western medicine, depressor such as various diuretic, beta receptor blocker, calcium ion antagonist, vasotonia corotation change enzyme inhibitor etc., but multi-angle produces hypotensive effect, and hypoglycemic medicine mainly contains insulin, minidiab, diamicron, metformin, acarbose etc.Lipid lowerers has lovastatin, simvastatin, gemfibrozil etc., and western medicine not only drug effect is single, and costs an arm and a leg, and side effect is big, as hypoglycemic reaction, the gastrointestinal reaction that depressor causes, and lesions of liver and kidney etc.In a word in the cardiovascular disease in recent years, most of patient all has hypertension, blood fat height, blood glucose height, combination situation that blood viscosity is big, uses present Drug therapy, need various Drug therapy sides to prove effective, and various side effect is full of contradictions.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition for promoting blood circulation and preparation method thereof, this pharmaceutical composition pill is a pure Chinese medicinal preparation, has benefiting QI for activating blood circulation, row to stagnate and to promote blood circulation, effects such as blood fat reducing, blood pressure lowering, and curative effect is good, do not increase the gastric burden after taking.
Pharmaceutical composition for promoting blood circulation provided by the present invention is by Radix Astragali 6-8 part, Radix Polygoni Multiflori 4-6 part, Radix Salviae Miltiorrhizae 6-8 part, Ganoderma 3-5 part, Radix Notoginseng 2-4 part, Rhizoma Chuanxiong 2-4 part, Radix Paeoniae Rubra 3-5 part, Rhizoma Alismatis 3-5 part, Fructus Crataegi 6-8 part, Hirudo 2-4 part, Folium Nelumbinis 2-4 part forms pill according to the prepared of traditional water pill.In preparation process, it is standby that the part medical material was directly pulverized No. 6 sieves, and part medical material water decocts and carries 2 times, and each 1 hour, the medicinal liquid of filtration simmer down to relative density d=1.08-1.10 (50 ℃), the two is sticking mutually and become ball promptly.
In preparation process, the Radix Astragali in the above-mentioned prescription, Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Rhizoma Alismatis powder can be broken into fine powder, cross sieve No. 6, standby, Radix Polygoni Multiflori, Ganoderma, Hirudo, Fructus Crataegi, Folium Nelumbinis are decocted with water 2 times each 1 hour, filter, merging filtrate is concentrated into relative density 1.08~1.10 (50 ℃), with the general ball of above-mentioned medicated powder, drying, polishing.
Hyperlipemia belongs to the traditional Chinese medical science " expectorant is turbid " " turbid damp " category.Because with the passing of time the foul smell of diet water paddy, stagnation turn to phlegm-damp, the stasis of blood stagnates obstructed and pathogenic.This disease is characteristics with the deficiency in origin and excess in superficiality generally, and deficiency in origin shows as the deficiency of vital energy more, especially based on the spleen deficiency of kidney-QI; Mark is real, then for water wets that cream fat changes that living expectorant is turbid, turbid damp, the stagnation of QI, blood stasis.So control with the dispel method of turbid blood stasis dispelling of benefiting QI for activating blood circulation.
Ten Herba indigoferae Pseudotinctoriae in the prescription of pharmaceutical composition for promoting blood circulation of the present invention:
1, the Radix Astragali mainly contains triterpene saponin (mainly being main component with the astragaloside), flavone compound and polysaccharide.
2, Radix Salviae Miltiorrhizae mainly contains fat-soluble diterpene quinones (TANSHINONES, cryptotanshinone etc.) and water miscible phenolic acids (Radix Salviae Miltiorrhizae acid, danshensu, caffeic acid etc.) composition.In addition, also contain compositions such as flavonoid, triterpenes and sterol.
3, Radix Notoginseng contains ginsenoside, arasaponin, flavonoid glycoside, Radix Notoginseng polysaccharide etc.
4, Rhizoma Chuanxiong mainly contains volatile oil, ferulic acid and crystallization phenolic substance etc.
5, Radix Paeoniae Rubra mainly contains peoniflorin, hydroxyl Radix Paeoniae, glycosides benzoylpaeoniflorin etc.
6, Rhizoma Alismatis contains multiple tetracyclic triterpene keto-alcohol derivant, sesquiterpenoids, cupreol and various trace elements etc.
7, ganoderan, triterpenoid compound, peptide, aminoacid, protein, adenosine, organic acid, alkaloid etc.
8, Radix Polygoni Multiflori contains anthraquinone analog compound (mainly containing emodin, chrysophanol, chrysophanic acid, physcione, physcione-8-O-β-D-glucoside etc.), stilbene glucoside, amide compound, chromone compounds, cachou extract and various trace elements etc.
9, Hirudo mainly contains protein, hirudin, aminoacid, heparin etc.
10, Fructus Crataegi mainly contains organic acid (citric acid, malic acid, succinic acid, ursolic acid, oleanolic acid, chlorogenic acid etc.) and flavone compound (hyperin, Quercetin, rutin etc.).
11, Folium Nelumbinis contains multiple alkaloid, flavonoid, organic acid, cupreol etc.
The Radix Astragali is the key medicine of QI invigorating in the side, and benefiting qi and raising yang is mended all empty deficiencies, makes the prosperous then blood of gas capable, to effect a permanent cure; Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling and battalion promote blood circulation; Two medicines share and contain blood circulation promoting and blood stasis dispelling among tonifications, are monarch drug altogether.The Radix Polygoni Multiflori invigorating the liver and kidney, benefiting essence-blood makes kidney essense vigour prosperous; Ganoderma helps the Radix Astragali, Radix Polygoni Multiflori benefiting QI and nourishing blood, strengthens healthy energy; Radix Notoginseng, Rhizoma Chuanxiong, Radix Paeoniae Rubra help Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, eliminating stagnation, and five is ministerial drug altogether.The Rhizoma Alismatis promoting diuresis to eliminate damp pathogen, " supporting the five internal organs, physical strength profiting ", its energy of Compendium of Material Medica cloud " eliminating dampness by diuresis heat, row phlegm retention ", " book on Chinese herbal medicine covers an aromatic plant metioned in ancient books " calls its " rush down FUSHUI, going or staying is dirty "; The hawthorn digesting eliminate indigestion, blood circulation promoting and blood stasis dispelling, greasy, the meat stagnation that disappears, Tang Rong river cloud: " blood stasis dispelling blood then expectorant water disappears certainly ", phlegm retention is ruled together; Go into network with Hirudo again and search heresy, the removing blood stasis collateral dredging, the three is adjuvant drug altogether.The Folium Nelumbinis sending up the lucid YANG helps all medicines current and for making.This side's strengthening vital QI to eliminate pathogenic factors: benefiting vital QI and blood and help operation, blood circulation promoting and blood stasis dispelling and promote blood circulation, row stagnates, change turbid, blood fat reducing, full side plays benefiting QI for activating blood circulation altogether, the row turbid merit of dispelling that stagnates.
The modern pharmacological research prompting, the Radix Astragali has the blood vessel dilating blood circulation promoting, reduces effects such as viscosity of blood; Ganoderma can alleviate the formation of aorta wall atherosclerotic plaque, resists myocardial ischemia the merit of blood fat reducing again; Radix Salviae Miltiorrhizae, Radix Notoginseng, Radix Paeoniae Rubra can improve the platelet 26S Proteasome Structure and Function, improve dense, sticking, the poly-state of blood, promote the metabolism of lipid material, the blood vessel dilating blood flow increasing, and microcirculation improvement has antithrombotic, lipid-reducing function; Radix Salviae Miltiorrhizae, Radix Polygoni Multiflori, Fructus Crataegi can promote the metabolism of lipid material and suppress the interior absorption to lipid material of body, reduce the deposition of lipid material in blood vessel wall, reduce lipid material level in the blood; Rhizoma Chuanxiong can reduce TC, TG, LDL-C, rising HDL-C, improves hemorheology, suppresses platelet aggregation, the protection blood vessel wall; Rhizoma Alismatis has blood fat reducing, the formation of atherosclerosis speckle, antithrombotic function; Folium Nelumbinis can reduce triacylglycerol, beta lipoprotein cholesterol and whole blood specific viscosity, the content of rising HDL-C, ApoA; Hirudo can reduce TC, TG, thereby helps recovering the normal of blood lipid metabolism.
Avirulence composition and contemporary toxicology proved deleterious medical material during prescription was formed, and prescription is formed no eighteen incompatible medicaments, nineteen medicaments of mutual restraint incompatibility, and the flavour of a drug consumption does not surpass the drug standard regulation.
Pharmaceutical composition for promoting blood circulation toxicity test of the present invention:
Experimental animal: the ICR mice, body weight 18.5g-20.5g provides licence by zooscopy institute of unming Medical College center: SCXK (Yunnan) 2005-0008
Use medicine:, get 20g behind the porphyrize and add water to the test liquid that the 80ml mixing is 25% (W/V is in crude drug in whole 39%) with pharmaceutical composition for promoting blood circulation of the present invention.
Test method: get 22 of mices, male and female half and half are irritated stomaches three times in the filling stomach volume of the drug level with 25%, 40ml/kg one day and are given a kind of blood vessels beneficial pharmaceutical composition preparation, normally raise after the administration, observe seven days continuously.
The result: 22 mices are all not dead in seven days after administration, and outward appearance, behavioral activity, the mental status, appetite, defecation and color thereof, all normal by hair, the colour of skin, breathing, the also no abnormal secretions in oral cavity, body weight is increased to 25.8+-1.1g by 19.5+_0.5g, this result shows that a kind of pharmaceutical composition for promoting blood circulation irritates stomach and reach 30g/kg (count 46.8g/kg with crude drug in whole, be 120 times with maximal dose 15g/60kg of the clinical day for human beings) for the mice daily dose to irritate stomach and give mice and do not cause that animal acute toxicity reacts.
The composition medicine of said preparation is the medical material that Chinese Pharmacopoeia or Yunnan Province's drug standard are put down in writing, and foundation is safely and effectively arranged.
The specific embodiment
Embodiment 1, Radix Astragali 200g, Radix Salviae Miltiorrhizae 240g, Radix Polygoni Multiflori 180g, Ganoderma 140g, Radix Notoginseng 80g, Rhizoma Chuanxiong 80g, Radix Paeoniae Rubra 160g, Rhizoma Alismatis 120g, Fructus Crataegi 240g, Hirudo 100g, Folium Nelumbinis 80g.
More than ten simply, get the Radix Astragali, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Folium Nelumbinis, Radix Paeoniae Rubra, Radix Notoginseng powder and be broken into fine powder, cross sieve No. 6, standby.Surplus medicine decocts with water 2 times, and each 1 hour, filter, merging filtrate is concentrated into relative density 1.10 (50 ℃), and with the general ball of above-mentioned medicated powder, drying, 1000g is made in polishing, promptly.
Embodiment 2, Radix Astragali 280g, Radix Salviae Miltiorrhizae 240g, Radix Polygoni Multiflori 200g, Ganoderma 120g, Radix Notoginseng 80g, Rhizoma Chuanxiong 80g, Radix Paeoniae Rubra 120g, Rhizoma Alismatis 120g, Fructus Crataegi 240g, Hirudo 80g, Folium Nelumbinis 80g.
More than ten simply, get Radix Polygoni Multiflori, Radix Salviae Miltiorrhizae, Ganoderma, Radix Notoginseng, Radix Paeoniae Rubra, Rhizoma Alismatis powder and be broken into fine powder, cross sieve No. 6, standby.Surplus medicine decocts with water 2 times, and each 1 hour, filter, merging filtrate is concentrated into relative density 1.10 (50 ℃), and with the general ball of above-mentioned medicated powder, drying, 1000g is made in polishing, promptly.
Embodiment 3, Radix Astragali 240g, Radix Salviae Miltiorrhizae 240g, Radix Polygoni Multiflori 160g, Ganoderma 120g, Radix Notoginseng 80g, Rhizoma Chuanxiong 80g, Radix Paeoniae Rubra 120g, Rhizoma Alismatis 120g, Fructus Crataegi 240g, Hirudo 80g, Folium Nelumbinis 80g.
More than ten simply, get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Rhizoma Alismatis powder and be broken into fine powder, cross sieve No. 6, standby.Surplus medicine decocts with water 2 times, and each 1 hour, filter, merging filtrate is concentrated into relative density 1.08 (50 ℃), and with the general ball of above-mentioned medicated powder, drying, 1000g is made in polishing, promptly.
The clinical research scheme:
Pharmaceutical composition for promoting blood circulation of the present invention is mainly used in the treatment hyperlipemia, is oral pills.According to the requirement of the clinical research guideline of " new Chinese medicine clinical research guideline " relevant hyperlipemia of nineteen ninety-five version, draft its clinical research scheme.
The clinical implementation scheme: this product is the Chinese medicine for oral administration pill, the principle that clinical observation is followed at random, contrasted, and 70 examples are organized in treatment, matched group 50 examples; The contrast medicine is a SHUXIN JIANGZHI JIAONANG; Be 20 days the course of treatment.
Observation index:
(1) safety is observed: general health check-up project; Blood, urine, just conventional; The heart, liver, kidney function test.
(2) health giving quality is observed: symptom: above-mentioned main clinical manifestation; Body weight (once in a week); Check: lipids contents such as cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, LDL are measured.
Curative effect determinate standard
(1) produce effects: clinical symptoms, sign disappear substantially, and lipids detection reaches following any one person, and promptly TC descends 〉=20%, and TG descends 〉=40%, HDL-C rising 〉=0.26mmol/L, and HDL-C/LDL-C descends 〉=20%.
(2) effective: lipids detection reaches following any one person, promptly TC descend 〉=10% but<20%, TG descend 〉=20% but<40%, HDL-C risings 〉=0.104mmol/L but<0.26mmol/L, HDL-C/LDL-C decline 〉=10% but<20%mmol/L.
(3) invalid: treatment back symptom, sign and lipids detection do not have obvious improver.
Untoward reaction please be recorded faithfully as untoward reaction occurring.
Clinical efficacy is summed up: use a kind of blood vessels beneficial pharmaceutical composition treatment hyperlipemia 56 examples, clinical efficacy is satisfied, is summarized as follows:
With reference to treating the hyperlipemia diagnostic criteria in " new Chinese medicine clinical research guideline ": under the normal diet situation, in 2 weeks as survey for 2 times serum total cholesterols (TC) all 〉=6.0mmol/L or triglyceride (TG) 〉=1.54mmol/L or high density lipoprotein (HDL-C) male≤1.04mmol/L, women≤1.17mmol/L person, can make a definite diagnosis.
Select case 99 examples with reference to " new Chinese medicine clinical research guideline ".Age 28-65 year.Male's 58 examples, women's 41 examples.Deficiency of spleen-YANG and kidneyYANG pattern of syndrome 47 examples, qi depression to blood stasis pattern of syndrome 52 examples; The course of disease the shortest half a year, the longest 8 years.Be divided into treatment at random and organize 56 examples, matched group 43 examples.Learn to handle by statistics (P>0.05), two groups have comparability at aspects such as age, sex, the courses of disease.
The oral pharmaceutical composition for promoting blood circulation of treatment group according to embodiment 3 preparations, 3 times/d, 5g/ time; The oral SHUXIN JIANGZHI JIAONANG of matched group, 3 times/d, 4/time.20 days is a course of treatment, judges curative effect after 2 courses of treatment.
Observation of curative effect: observation index is the fat 1 time of having a blood test in per 10 days, and result before and after the treatment relatively.
Therapeutic outcome:
After two groups of medications therapeutic outcome see the following form 1, table 2.
Table 1. liang group curative effect relatively
Group | n | Produce effects (%) | Effectively (%) | Invalid (%) | Total effective rate (%) | The P value |
Treatment group matched group | 56 43 | 36(64.3) 24(55.8) | 17(30.3) 11(25.6) | 3(5.4) 8(18.6) | 94.6 81.4 | <0.05 |
Blood Lipid before and after table 2. treatment (x ± s)
Group | n | TC | TG | HDL | |
Treatment group matched group | 56 43 | After treating before the preceding treatment of the treatment back treatment | 6.85±0.23 5.17±0.39* 6.86±0.35 5.72±0.38 | 2.71±0.36 1.27±0.30* 2.80±0.28 2.46±0.37 | 1.02±0.29 1.47±0.24* 1.05±0.32 1.23±0.35 |
*P<0.01
According to data demonstration as a result, Xuezhikang pharmaceutical composition pill has good effect for reducing fat, can effectively reduce TC, TG, and improve HDL, thereby can treat hyperlipemia, thus the protection cardiovascular and cerebrovascular vessel, an easily rate of slow down arteriosclerotic generation and reduction coronary heart disease.Said preparation is held concurrently with blood circulation promoting and blood stasis dispelling based on QI invigorating, and treating both the principal and the secondary aspects of a disease at the same time so not only obtained short term effect preferably, has also obtained gratifying late result.In the middle of the use, do not find untoward reaction, the clinical expansion applying value is arranged.
Clinical case:
Case 1: Zhang Ping, man, 38 years old, trade, build fat partially (height 1.70m, body weight 78Kg).Nearly March is felt dizzy in readme, and spiritlessness and weakness is ached all over, poor appetite.Look into: light red tongue, tongue are greasy in vain, deep-thready pulse.Lipids detection: TC 7.1mmol/L, TG 1.8mmol/L, HDL 1.02mmol/L.Diagnosis: hyperlipemia, the traditional Chinese medical science belongs to yang deficiency of spleen and stomache.Treatment: oral pharmaceutical composition for promoting blood circulation every day 3 times, each 5g serve on 2 courses of treatment (40 days).Lipids detection: TC 5.6mmol/L, TG1.48mmol/L, HDL 1.11mmol/L is normal value; And above-mentioned symptom disappears.Continue and obey 2 courses of treatment, to consolidate curative effect.Follow up a case by regular visits to after half a year, the lipids detection index is stable, and body weight alleviates (70Kg) to some extent.
Case 2: Zhou Fanghui, woman, 56 years old, teacher.It is dizzy weak that readme is felt closely over the past half year, sensation of oppression over the chest with shortness of breath, sternal rib pain.Look into: the tip of the tongue has petechia, deep and hesitant pulse.Lipids detection: TC 7.6mmol/L, TG 1.62mmol/L, HDL 0.92mmol/L.Diagnosis: hyperlipemia, the traditional Chinese medical science belongs to qi stagnation and blood stasis type.Treatment: oral pharmaceutical composition for promoting blood circulation every day 3 times, each 5g serve on 2 courses of treatment (40 days).Lipids detection: TC 5.8mmol/L, TG 1.49mmol/L, HDL 1.21mmol/L is normal value; And above-mentioned symptom disappears.Continue and obey 2 courses of treatment, to consolidate curative effect.Follow up a case by regular visits to after half a year, the lipids detection index is stable, and conscious health is good.
Claims (3)
1, a kind of pharmaceutical composition for promoting blood circulation, it is characterized in that component: Radix Astragali 6-8 part, Radix Polygoni Multiflori 4-6 part, Radix Salviae Miltiorrhizae 6-8 part by following weight portion, Ganoderma 3-5 part, Radix Notoginseng 2-4 part, Rhizoma Chuanxiong 2-4 part, Radix Paeoniae Rubra 3-5 part, Rhizoma Alismatis 3-5 part, Fructus Crataegi 6-8 part, Hirudo 2-4 part, Folium Nelumbinis 2-4 part forms pill according to the prepared of traditional water pill.
2, a kind of preparation method of pharmaceutical composition for promoting blood circulation, it is characterized in that, it is standby that part medical material in the described component of claim 1 was directly pulverized No. 6 sieves, residue medical material water decocts to be carried 2 times, each 1 hour, filtering the simmer down to relative density is the medicinal liquid of d=1.08-1.10 (50 ℃), and the two sticking mutually and general ball, drying, polishing are promptly.
3, according to the preparation method of the described pharmaceutical composition for promoting blood circulation of claim 2, it is characterized in that, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong, Radix Paeoniae Rubra, Rhizoma Alismatis powder in the described component of claim 1 are broken into fine powder, it is standby to cross No. 6 sieves, Radix Polygoni Multiflori, Ganoderma, Hirudo, Fructus Crataegi, Folium Nelumbinis are decocted with water 2 times, each 1 hour, filter merging filtrate, be concentrated into relative density 1.08~1.10 (50 ℃), with the general ball of above-mentioned medicated powder, drying, polishing promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101638496A CN100488539C (en) | 2006-12-26 | 2006-12-26 | Pharmaceutical composition for promoting blood circulation and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006101638496A CN100488539C (en) | 2006-12-26 | 2006-12-26 | Pharmaceutical composition for promoting blood circulation and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1994403A true CN1994403A (en) | 2007-07-11 |
CN100488539C CN100488539C (en) | 2009-05-20 |
Family
ID=38249659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101638496A Expired - Fee Related CN100488539C (en) | 2006-12-26 | 2006-12-26 | Pharmaceutical composition for promoting blood circulation and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100488539C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614391A (en) * | 2012-05-03 | 2012-08-01 | 侯安会 | Traditional Chinese medicine for treating cerebrovascular disease and preparation method thereof |
CN103211929A (en) * | 2013-04-12 | 2013-07-24 | 刘长江 | Traditional Chinese medicine for treating cerebral thrombosis |
CN108634013A (en) * | 2018-04-20 | 2018-10-12 | 管天球 | A kind of preparation method for preventing cerebrovascular sclerosis tea oil |
CN116920062A (en) * | 2023-05-17 | 2023-10-24 | 南昌大学 | A kind of traditional Chinese medicine composition for treating cardiovascular diseases |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102335239B (en) * | 2011-07-25 | 2015-03-18 | 北京协和制药二厂 | Chinese medicinal composition for reducing blood fat and preparation method thereof |
-
2006
- 2006-12-26 CN CNB2006101638496A patent/CN100488539C/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614391A (en) * | 2012-05-03 | 2012-08-01 | 侯安会 | Traditional Chinese medicine for treating cerebrovascular disease and preparation method thereof |
CN103211929A (en) * | 2013-04-12 | 2013-07-24 | 刘长江 | Traditional Chinese medicine for treating cerebral thrombosis |
CN108634013A (en) * | 2018-04-20 | 2018-10-12 | 管天球 | A kind of preparation method for preventing cerebrovascular sclerosis tea oil |
CN116920062A (en) * | 2023-05-17 | 2023-10-24 | 南昌大学 | A kind of traditional Chinese medicine composition for treating cardiovascular diseases |
Also Published As
Publication number | Publication date |
---|---|
CN100488539C (en) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100457176C (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
CN101347563B (en) | Medicament for treating baldness and white hair and preparation method thereof | |
CN1994451B (en) | Chinese medicinal composition for treating depression, its preparation method and application | |
CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
CN100460008C (en) | Chinese medicine composition for treating cancer | |
CN100488539C (en) | Pharmaceutical composition for promoting blood circulation and preparation method thereof | |
CN102283951B (en) | Chinese medicinal composition for treating anaphylactoid purpura and thrombocytopenic purpura | |
CN101347557B (en) | Medicament composition for refreshment and intelligence development and preparation and use thereof | |
CN104940810A (en) | Traditional Chinese medicine composition for treating angina | |
CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN102512552B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
CN104922426A (en) | Pharmaceutical composition for treating post gynecologic operation low fever | |
CN103599455B (en) | Traditional Chinese medicine capsule for removing freckle | |
CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
CN113209194B (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
CN101745048B (en) | A drug for treating type Ⅱ diabetes and anti-aging | |
CN101564505B (en) | Chinese medicament for treating pulmonary heart disease | |
CN101502599A (en) | Medicament for treating constipation of old people and postpartum puerpera as well as preparation method | |
CN101129948B (en) | Pharmaceutical composition for treating gynecology hysteromyoma and processes for producing same | |
CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
CN103585366A (en) | Medicine for treating ischemic hyperlipidemia and preparation method thereof | |
CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090520 Termination date: 20211226 |